Medlingua Daily Rounds

Seats present: claude, codex, mistral, gemini, groq, cerebras, nvidia Seats missing: glm (no key configured) Seats with failed calls: cerebras (5 call(s) failed), gemini (4 call(s) failed), nvidia (1 call(s) failed)

Synthesis

Seats: Seats present: claude, codex, mistral, gemini, groq, cerebras, nvidia. Seats missing: glm (no key configured). Seats with failed calls: cerebras (5 calls failed — contributed no takes despite being seated), gemini (4 calls failed — contributed only a capital-allocator take), nvidia (1 call failed — no operator take). Consensus below rests mainly on claude, codex, groq, and mistral, which completed all five personas.

Consensus

• Value today is ~$0; at most a $200–$500 validation experiment. Every capital-allocator seat independently priced the idea at or near zero and refused to fund an app build (claude, codex, gemini, groq, mistral, nvidia).
• Liability is the central unresolved question. All seats across all personas flag Title VI / malpractice exposure: a product that makes clinicians confident enough to skip a certified interpreter makes hospitals less likely to buy it. The only defensible positioning is an explicit supplement — rapport, comfort, workflow phrases — never history-taking or consent.
• The physics doesn't support the pitch. 5 min/day × two months ≈ 5 hours of exposure; claude, codex, and groq independently note this buys 100–200 scripted phrases, not comprehension or proficiency.
• Content validation, not software, is the cost. The app is a weekend build; clinically reviewed, dialect-aware content is the expensive, decaying asset — and offers no moat against Canopy Learn, which already ships this with CME credit.
• The five unanswered interview questions are the finding. Multiple seats state the answers are the business; the app is the cheap part.

Live disagreements

• Is there a channel at all? claude and nvidia (distribution) see a real, well-timed channel in short-form clinical video for anxious residents/nurses (MedTok/NurseTok, July intern start); groq and mistral call that channel a ghost — clinicians are risk-averse, skeptical of quick-fix apps, and won't share.
• Kill now vs. cheap test. mistral ("kill the idea", "DOA") and groq lean immediate pivot; claude, codex, and nvidia say a small preorder/pilot test is worth two weekends.
• Content cost magnitude. Estimates for one validated language span $25–28k (claude, codex) to ~$100k (nvidia) to $250–500k (groq) — an order-of-magnitude open question.
• If pivoting, to what? groq: real-time translation copilot or documentation tools; nvidia: EHR-integrated micro-lessons keyed to the next patient; claude: LLM speech roleplay attacking comprehension; mistral: non-clinical staff (front desk, medical assistants).

Kill criteria

Drop this idea if any of the following is observed:

1. Fewer than 10 paid preorders at $29–49 from ~100–200 targeted clinicians within two weeks of a landing-page test.
2. Five hospital compliance/risk-officer interviews yield zero written willingness to pilot even a supplement-positioned version within 30 days.
3. A malpractice attorney or insurer opines that the product creates non-disclaimable liability for users or the developer.
4. Clinical review of a 50-phrase sample costs over ~$50/phrase or rejects a large fraction as unsafe/irrelevant, confirming the high end of content-cost estimates.
5. Week-4 completion in a free pilot falls below ~30% — the "5 minutes a day" habit doesn't survive contact with clinicians' schedules.

Next actions

1. Answer Q1 and Q4 in writing (who pays; supplement-vs-replacement positioning) before any other work — every seat treats these as gating.
2. Run the $500 demand test: 50 clinician-reviewed rapport/triage phrases plus a landing page with a $29–49 preorder, pushed to one specialty cohort for two weeks; measure paid conversions against kill criterion #1.
3. Interview 5 hospital compliance/risk officers and one malpractice attorney on whether an interpreter-supplement tool is approvable, capturing responses in writing against kill criteria #2–3.

Dissent

By: codex

• “Every allocator independently” is overstated. These are correlated models answering the same framing, not independent market evidence. Three nominally present seats contributed partially or not at all; the “consensus” is effectively four models recycling similar priors.

• Liability is asserted, not analyzed. The synthesis conflates Title VI compliance, malpractice, institutional policy, and developer product liability. None automatically makes a phrase-learning tool dangerous. The relevant comparison is existing language courses, not certified interpreting during care. Conversely, “supplement” disclaimers may not control actual use.

• The exposure math attacks a strawman. Five hours plainly cannot create proficiency, but the pitch may only require recall of a narrow phrase set. The council never defines the promised competency or tests whether 100–200 phrases produce useful rapport.

• “Weekend app” is convenient hand-waving. Speech scoring, audio quality, dialect variants, accessibility, analytics, authentication, privacy, and safe clinical UX are not weekend work. Meanwhile, the $25k–$500k content estimates are unsupported guesses, so they cannot anchor a decision.

• Canopy Learn is treated as dispositive without competitive analysis. Existing content plus CME proves a market may exist; it does not establish customer satisfaction, pricing power, retention, specialty coverage, or whether a narrower product can differentiate.

• The demand test is badly identified. Ten preorders from 100–200 clinicians measures audience access, creative quality, and trust as much as demand. Fifty phrases are not enough to demonstrate the habit or outcome. A two-week failure could wrongly kill the idea.

• The compliance criterion is nearly designed to fail. Risk officers rarely provide “written willingness” before security, efficacy, procurement, and clinical-owner review. Five interviews cannot estimate institutional demand.

• One attorney or insurer opinion is not a kill switch. Scope, jurisdiction, claims, warnings, evidence, and policy design determine exposure.

• Missing: patient/interpreter perspectives, observed workflow research, buyer versus user, language/specialty selection, efficacy endpoints, reimbursement/CME economics, procurement cycle, and incumbent usage data.

• Survives attack: validate positioning, buyer, safety boundaries, and paid demand before funding a full build.

Decision

(Yours to write by hand. The council never decides for you and never posts anything anywhere.)